VAXNEWMO, LLC
Biotech · Private
Multivalent conjugate vaccine against Klebsiella pneumoniae manufactured using proprietary bioconjugation platform
- Grants
- $11M
- 17 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 24
- 6 granted · 18 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines | $210,129 | |
| Federal grant | Department of Health and Human Services · Phase I · Glycoengineering a bioconjugate vaccine against Klebsiella pneumoniae | $299,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a bioconjugate vaccine against Group B Streptococcus | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines | $931,060 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a bioconjugate vaccine against Group B Streptococcus | $280,104 | |
| Federal grant | Department of Health and Human Services · Phase II · Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines | $992,959 | |
| Federal grant | Department of Health and Human Services · Phase I · A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines | $984,934 | |
| Federal grant | Department of Health and Human Services · Phase II · A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections | $299,238 | |
| Federal grant | Department of Health and Human Services · Phase I · A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections | $293,112 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Group B Streptococcus bioconjugate vaccine | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections | $298,254 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Group B Streptococcus bioconjugate vaccine | $995,682 | |
| Federal grant | Department of Health and Human Services · Phase II · A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections | $994,178 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Group B Streptococcus bioconjugate vaccine | $995,682 | |
| Federal grant | Department of Health and Human Services · Phase II · A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections | $999,717 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1104 | ANCHORCHEM LLC | — | — |
| 1105 | Vault Nano Inc | — | — |
| 1106 | Pretzel Therapeutics | — | — |
| 1107 | VAXNEWMO, LLC | — | — |
| 1108 | EUGIT THERAPEUTICS, INC. | — | — |
| 1109 | Proximity Biosciences LLC | — | — |
| 1110 | EMMUNE INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Glycosylated Comp Pilin Variants, Methods Of Making And Uses Thereofgranted
- O-linked Glycosylation Recognition Motifsgranted
- Minimal Sequons Sufficient for O-Linking Glycosylationapplication
- Glycosylated Comp Pilin Variants, Methods Of Making And Uses Thereofgranted
- Klebsiella Pneumoniae O-Antigen Glycosylated Proteins and Methods of Making and Uses Thereofapplication
- Acinetobacter O-Oligosaccharyltransferases and Uses Thereofgranted
- Acinetobacter O-Oligosaccharyltransferases and Uses Thereofgranted
- Acinetobacter O-oligosaccharyltransferases And Uses Thereofgranted
- Klebsiella Pneumoniae O-antigen Glycosylated Proteins And Methods Of Making And Uses Thereofapplication
- Minimal Sequons Sufficient for O-Linking Glycosylationapplication
- Klebsiella Pneumoniae O-Antigen Glycosylated Proteins and Methods of Making and Uses Thereofapplication
- O-linked Glycosylation Recognition Motifsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.